Immucell (ICCC) EV to EBIT (2010 - 2026)

Immucell (ICCC) has reported EV to EBIT for 17 consecutive years, with 42.59 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EV to EBIT fell 57.41% year-over-year to 42.59; the trailing twelve-month figure through Jun 2026 stood at 33.41 (up 1.7% YoY), and the FY2025 full-year result was 31.42, up 221.31% from the prior year.
• EV to EBIT grew to 42.59 in Q2 2026 per ICCC's latest filing, from 894.22 in the prior quarter.
• Across five years, EV to EBIT topped out at 2622.68 in Q3 2025 and bottomed at 894.22 in Q4 2025.
• Historically, EV to EBIT has averaged 100.04 across 5 years, with a median of 25.91 in 2022.
• The widest YoY moves for EV to EBIT: up 5436.18% in 2025, down 1407.93% in 2025.
• Over 5 years, EV to EBIT stood at 25.38 in 2022, then sank by 31.04% to 33.26 in 2023, then soared by 305.57% to 68.37 in 2024, then sank by 1407.93% to 894.22 in 2025, then surged by 104.76% to 42.59 in 2026.
• According to Business Quant data, EV to EBIT over the past three periods registered 42.59, 894.22, and 2622.68 for Q2 2026, Q4 2025, and Q3 2025 respectively.